Pending trial results supporting prescribers’ efficacy and safety demands, gene therapies are poised to capture upwards of one-fifth of the AMD, GA and DME.
Although crowded, the RA market contains clear pathways for existing players and new entrants to navigate the evolving landscape and expand their market.
Charting New Paths: Non-TNF's Evolving in Rheumatoid Arthritis Market eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.
EXTON, PA, Feb. 22, 2024 (GLOBE NEWSWIRE) The 2023 announcement of newly approved disease-modifying therapy (DMT) Leqembi (lecanemab) for Alzheimer’s Disease (AD) sparked eager anticipation within both the medical